DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Beraprost
Beraprost
Clinical Trial Protocol: BPS-314D-MR-PAH-302
Effect of Prostanoids on Human Platelet Function: an Overview
Antiplatelet Effects of Prostacyclin Analogues: Which One to Choose in Case of Thrombosis Or Bleeding? Sylwester P
Prostacyclin Therapies for the Treatment of Pulmonary Arterial Hypertension
Jp Xvii the Japanese Pharmacopoeia
Nippon Shinyaku (4516)
Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
Recent Advances in Targeting the Prostacyclin Pathway in Pulmonary Arterial Hypertension
Harnessing DNA-Encoded Libraries to Discover Bioactive Small Molecules
Antithrombin and Its Role in Host Defense and Inflammation
The Roles of Various Prostaglandins in Fibrosis: a Review
Reproductive Health Guideline Appendix 3 – Search Strategies
Download Product Insert (PDF)
Comparing the Vascular Thromboembolic Events Following
Long Term Treatment of Pulmonary Arterial Hypertension with Beraprost, an Oral Prostacyclin Heart: First Published As 10.1136/Heart.86.6.661 on 1 December 2001
Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment Of
Studies on the Ešectiveness and Safety of Cilostazol, Beraprost Sodium, Prostaglandin E1 for the Treatment of Intermittent Claudication
Search Strategy Systematic Review of Effect of Statins and Antiplatelets On
Top View
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Project SCYLLA
Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting
Effects of Beraprost Sodium, an Oral Prostacyclin Analogue, in Patients
Antiplatelet Agents for Chronic Kidney Disease (Review)
Beraprost Modified Release in Addition to Treprostinil for Pulmonary Arterial Hypertension
Pharmacological Interventions for the Prevention of Fetal Growth Restriction: Protocol for a Systematic Review and Network Meta-Analysis
Pulmonary Arterial Hypertension in Children
Pharmaceutical Compositions Comprising Prasugrel And
NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
Recent Progress and Market Analysis of Anticoagulant Drugs
Beraprost (Beraprost-314D) on Pulmonary Vascular Tone, IP Receptors and Human Smooth Muscle Proliferation in Pulmonary Hypertension
Prostanoid Therapy for Pulmonary Arterial Hypertension David B
Tissue‐Resident Macrophages Actively
Oral Beraprost Sodium As a Prostaglandin 12
Tissue‐Resident Macrophages Actively Suppress IL
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Biotechnology Corticosteroids & Hormones Synthesis Prostaglandins
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Pharmaceutical Appendix to the Tariff Schedule 2
Bronchodilation Induced by PGE2 Is Impaired in Group-III Pulmonary Hypertension
Pharmaceutical Appendix to the Tariff Schedule 2
Beraprost Sodium, a Stable Prostacyclin Analogue, Improves Insulin Resistance in High-Fat Diet-Induced Obese Mice
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
Bronchodilation Induced by PGE2 Is Impaired in Group-III Pulmonary Hypertension
Therapeutic Class Overview Platelet Inhibitors
Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: a Systematic Review and Meta-Analysis
Pharmaceutical Appendix to the Tariff Schedule 2
WO 2012/123502 Al 20 September 2012 (20.09.2012) P O P C T
Production of Prostaglandin E2 and I2 Is Coupled with Cyclooxygenase-2 in Human Follicular Dendritic Cells
Effects of Antithrombotic Drugs on the Results of Fecal Immunochemical
Product List 2020 BIOTECH and FERMENTATION PROSTAGLANDINS CORTICOSTEROIDS & HORMONES SYNTHESIS FRANCOPIA Product Name Business Unit Therapeutic Class ATC4 Page